Gilead Sciences, Inc.

Jun 26, 2020

Gilead Terminates License Agreement for Long-Acting Injectable HIV Investigational Product

Sep 09, 2019

DURECT Earns $10 Million Milestone Payment for Further Development of a Long-Acting Injectable HIV Investigational Product Utilizing DURECT's SABER® Technology

Jul 08, 2019

Grant & Eisenhofer Brings Mass Tort Lawsuits against Drugmaker Gilead over HIV Medications Containing TDF, Suits Move Forward in California State Court

May 30, 2019

Taiwan National Health Insurance Adminstration of the Ministry of Health and Welfare Approves Epclusa(R) (sofosbuvir/velpatasvir) for Reimbursement

Apr 30, 2019

Taiwan National Health Insurance Administration of the Ministry of Health and Welfare Approves Vemlidy(R) (tenofovir alafenamide) for Reimbursement

Apr 19, 2019

Mass Tort Alleges Gilead Sciences, Inc. Withheld Safer Drugs From HIV/AIDS Patients, Manipulated Patent Timing for Profit, Announces Jenner Law

Mar 13, 2019

Agenus Milestone Triggers $7.5M Payment from Gilead

Jan 24, 2019

Agenus Closes $150 Million Immuno-Oncology Transaction with Gilead

Dec 20, 2018

Gilead And Agenus Enter into Collaboration to Develop Immuno-Oncology Therapies

Oct 03, 2018

Hong Kong Department of Health Approves Biktarvy(R) (bictegravir, emtricitabine, tenofovir alafenamide)

Sep 12, 2018

Sutro Taps Worsley as Chief Business Officer; Names Fitzpatrick as People and Communications Chief